Antiretrovirals for HIV prevention: Translating promise into praxis

The Lancet

Volumn 378, Issue 9787, 2011, Pages 206-208

  Mayer, Kenneth H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; TENOFOVIR;

AFRICAN AMERICAN; DISEASE TRANSMISSION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALE; NOTE; PRIORITY JOURNAL;

EID: 79960371054     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61056-8     Document Type: Note

References (10)

1. Q Abdool Karim, SS Abdool Karim, JA Frohlich for the CAPRISA 004 Trial Group Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science 329 2010 1168 1174
2. RM Grant, JR Lama, PL Anderson for the iPrEx study team Preexposure chemoprophylaxis for HIV prevention in men who have sex with men N Engl J Med 363 2010 2587 2599
3. NIH News Treating HIV-infected people with antiretrovirals protects partners from infection: findings result from NIH-funded international study http://www.niaid.nih.gov/news/newsreleases/2011/Pages/HPTN052.aspx (accessed June 29, 2011).
4. Family Health International FHI statement on the FEM-PrEP HIV prevention study http://minilicious.wordpress.com/2011/04/18/fhi-statement-on-the-fem-prep- hiv-prevention-study/ (accessed June 28, 2011).
5. SS Abdool Karim, A Kashuba, L Werner, Q Abdool Karim Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women Lancet 378 2011 279 281
6. Hendrix C, Minnis A, Guddera V, et al. MTN-001: a phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA. Feb 27-March 22, 2011. 35LB (abstr).
7. Patterson KB, Prince HA, Kraft E, et al. Exposure of extracellular and intracellular tenofovir and emtricitabine in mucosal tissues after a single of fixed-dose TDF/FTC: implications for pre-exposure HIV prophylaxis (PrEP). XVIII International AIDS Conference; Vienna, Austria. July 18-23, 2010. THBS0305 (abstr).
8. UNAIDS UNAIDS report on the global AIDS epidemic 2010 2010 joint United Nations programme on HIV/AIDS Geneva http://www.unaids.org/globalreport/ (accessed Feb 11, 2011).
9. AD Paltiel, KA Freedberg, CA Scott et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness Clin Infect Dis 48 2009 806 815
10. Walensky R, Park J-E, Wood R, et al. Cost effectiveness of PrEP for HIV infection in South Africa. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA. Feb 27-March 22, 2011. 37LB (abstr).